Form 4: Viatris Officer Enrietti Reports Equity Award Vesting

Viatris Inc. Chief Administrative and Transformation Officer Andrew Enrietti reported the vesting and settlement of restricted stock units and performance restricted stock units, alongside tax-related share withholdings.

Summary

• Andrew Enrietti, Chief Administrative and Transformation Officer of Viatris Inc., reported multiple transactions related to his beneficial ownership of Viatris common stock.
• Transactions on March 3, 2026, included the acquisition of 11,531 shares from vested Restricted Stock Units (RSUs), 1,709 shares from Dividend Equivalent Units (DEUs), and 110,630 shares from vested Performance Restricted Stock Units (PRSUs).
• On the same date, 5,094 shares, 744 shares, and 48,113 shares were disposed of to cover tax liabilities associated with the vesting of RSUs, DEUs, and PRSUs, respectively, at a price of $14.89 per share.
• Transactions on March 4, 2026, included the acquisition of 13,568 shares from vested RSUs and 1,279 shares from DEUs.
• On March 4, 2026, 5,901 shares and 557 shares were disposed of to cover tax liabilities associated with the vesting of RSUs and DEUs, respectively, at a price of $14.71 per share.
• Following these transactions, Andrew Enrietti's direct beneficial ownership of Viatris common stock was 208,308 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine vesting of executive compensation and the officer's continued equity stake in the company, which aligns interests with shareholders.

Positives

• The officer received a significant number of shares (11,531 RSUs, 1,709 DEUs, 110,630 PRSUs on March 3, 2026; 13,568 RSUs, 1,279 DEUs on March 4, 2026) through the vesting of equity awards, indicating successful attainment of performance goals for PRSUs and continued service for RSUs.
• The vesting of these awards represents a substantial increase in the officer's direct equity stake in Viatris, aligning management interests with shareholder value.

Negatives

• A significant number of shares were withheld (5,094, 744, 48,113 on March 3, 2026; 5,901, 557 on March 4, 2026) to cover tax liabilities, which is a common practice but reduces the net shares received by the officer.

Future Outlook

The filing indicates future vesting of 13,569 Restricted Stock Units on March 4, 2027, for the reporting person, suggesting continued equity compensation plans.

Industry Context

StockSavvy.ai notes that the vesting and settlement of equity awards, such as RSUs and PRSUs, are standard components of executive compensation packages across the pharmaceutical and healthcare industries. These mechanisms are designed to align executive incentives with long-term shareholder value creation and retention. The reported transactions are routine for an officer receiving performance-based compensation.

Stakeholder Impact

• Shareholders: The transactions reflect the ongoing compensation structure for a key executive, which is designed to align management incentives with shareholder interests.
• Employees: The equity awards are part of a broader compensation strategy that may influence employee retention and motivation, particularly for senior leadership.

Next Steps

• Vesting of 13,569 Restricted Stock Units on March 4, 2027, as part of the officer's compensation schedule.

Key Dates

Keywords

Viatris, VTRS, SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Performance Restricted Stock Units, Dividend Equivalent Units, Andrew Enrietti, Officer Ownership